Outcomes in children treated with growth hormone for Prader-Willi syndrome: data from the ANSWER Program® and NordiNet® International Outcome Study.

ABSTRACT: Background: Growth hormone (GH) deficiency is common in patients with Prader-Willi syndrome (PWS) and leads to short adult stature. The current study assessed clinical outcomes based on real-world observational data in pediatric patients with PWS who were treated with GH.

Methods: Data from patients previously naïve to treatment with GH who began therapy with somatropin were collected from 2006 to 2016 in the observational American Norditropin® Studies: Web-Enabled Research (ANSWER) Program® and NordiNet® International Outcome Study. Variables affecting change from baseline in height standard deviation scores (HSDS; n?=?129) and body mass index standard deviation scores (BMI SDS; n?=?98) were determined.

Results: Patients included in both HSDS and BMI SDS analyses were treated with a mean GH dose of 0.03?mg/kg/d (SD, 0.01?mg/kg/d). Results from the HSDS analysis revealed that baseline age and years on treatment had a significant impact on the change in HSDS. In the BMI SDS analysis, longer GH treatment time led to a greater change in BMI SDS from baseline, and patients with a higher BMI at the start of treatment had a greater decrease in BMI over time.

Conclusions: GH is effective in the management of children with PWS. Earlier treatment resulted in a greater gain in height, and a longer treatment period resulted in better outcomes for both height and BMI.

Trial registration: This study was registered with ClinicalTrials.gov ( NCT01009905 ) on November 9, 2009.

SUBMITTER: Angulo M 

PROVIDER: S-EPMC7653711 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature